Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 42Advanced Solid Tumor 27Solid Tumor 19Solid Tumors 17Mesothelioma, Malignant 8Mesothelioma 6Advanced Malignant Solid Tumor 6Solid Tumor Cancer 5Solid Tumor Malignancies 4Metastatic Solid Tumors 4Solid Tumor, Adult 3Malignant Solid Tumors 3Hematopoietic and Lymphatic System Neoplasm 3Advanced Malignant Solid Tumors 3Pancreas Adenocarcinoma (MSI-H) 2Ovarian Neoplasms 2Malignant Solid Neoplasm 2Locally Advanced or Metastatic Solid Tumors 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced/Metastatic Solid Tumors 2Advanced Solid Tumors Cancer 2mCRPC or Advanced/Metastatic Solid Tumors 1Unresectable Solid Tumors 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Treatment-Refractory Solid Tumors 1Solid Tumors, Adult 1Solid Tumors with FGFR2 Alterations, Adult 1

Interventions

atezolizumab 1Hydroxyurea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Treatment-Refractory Solid Tumors × Other solid neoplasm × Clear all
NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡